Sanofi $SNY Shares Acquired by First Trust Advisors LP

First Trust Advisors LP grew its stake in Sanofi (NASDAQ:SNY) by 2.4% during the first quarter, according to its most recent 13F filing with the SEC. The firm owned 767,835 shares of the company’s stock after acquiring an additional 17,880 shares during the period. First Trust Advisors LP’s holdings in Sanofi were worth $36,994,000 as of its most recent filing with the SEC.

Other hedge funds have also recently made changes to their positions in the company. Raymond James Financial Inc. raised its position in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares during the period. Capital Research Global Investors purchased a new position in shares of Sanofi during the fourth quarter worth $79,960,000. Morgan Stanley boosted its position in shares of Sanofi by 20.4% during the fourth quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock worth $441,093,000 after buying an additional 1,540,271 shares during the period. Manning & Napier Advisors LLC grew its stake in shares of Sanofi by 728,134.8% in the first quarter. Manning & Napier Advisors LLC now owns 1,194,305 shares of the company’s stock valued at $57,542,000 after buying an additional 1,194,141 shares in the last quarter. Finally, Franklin Resources Inc. grew its stake in shares of Sanofi by 29.7% in the fourth quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock valued at $247,151,000 after buying an additional 1,168,339 shares in the last quarter. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the company. Morgan Stanley set a $49.00 target price on Sanofi in a research note on Wednesday, July 8th. BNP Paribas Exane lowered shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research note on Monday, April 20th. Citigroup reissued a “neutral” rating on shares of Sanofi in a research report on Monday, April 13th. Wall Street Zen lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research note on Saturday, July 18th. Finally, Argus upgraded shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $49.50.

Sanofi Trading Up 1.5%

NASDAQ:SNY opened at $44.00 on Tuesday. Sanofi has a 12-month low of $40.89 and a 12-month high of $52.68. The firm has a market cap of $106.67 billion, a PE ratio of 12.29, a price-to-earnings-growth ratio of 1.10 and a beta of 0.34. The company has a current ratio of 1.01, a quick ratio of 0.22 and a debt-to-equity ratio of 0.17. The stock has a fifty day moving average price of $43.45 and a 200 day moving average price of $45.31.

Sanofi Company Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.